Innate Pharma SA Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Mar 21, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Mar 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, compliance
TL;DR
Innate Pharma SA filed a 6-K, standard compliance for foreign issuers.
AI Summary
On March 21, 2024, Innate Pharma SA filed a Form 6-K. This report is for a foreign private issuer and is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. The company is based in Marseille, France, and its principal executive office is located at 117 Avenue de Luminy. Innate Pharma SA is involved in the biological products industry, specifically excluding diagnostic substances.
Why It Matters
This filing indicates Innate Pharma SA is a foreign private issuer complying with US SEC reporting requirements, providing transparency for investors.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new financial or operational information that would typically indicate significant risk.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- 117 Avenue de Luminy (location) — Principal executive office address
- Marseille, France (location) — Company location
- 001-39084 (company) — SEC File Number
- 20240321 (date) — Filing date
FAQ
What type of SEC filing is this?
This is a Form 6-K report, filed by a foreign private issuer.
Who is the filer of this report?
The filer is Innate Pharma SA.
What is the filing date of this report?
The report was filed on March 21, 2024.
Where is Innate Pharma SA's principal executive office located?
The principal executive office is located at 117 Avenue de Luminy, Marseille, France.
Under which rules is this Form 6-K filed?
This Form 6-K is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Filing Stats: 205 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2024-03-21 06:01:15
Filing Documents
- a6k-iphx240321.htm (6-K) — 9KB
- exhibit991-240321.htm (EX-99.1) — 91KB
- 0001598599-24-000013.txt ( ) — 101KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date March 21, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive